Vivos Therapeutics, Inc. Common Stock
Here’s whether Vivos Therapeutics, Inc. Common Stock (VVOS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.20% over 10 days); RSI 74 — overbought, elevated pullback risk; weak 1-year return of -60.9%; 3-month momentum negative (-35.0%); rising volume on a downtrend (distribution, 2.86x avg). Currently 89.1% off its 52-week high. Score: -7/7.
VVOS is trading below its 200-day MA ($2.04) — a key warning sign the longer-term trend is under pressure. With an RSI of 74.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -60.9% compares to +24.4% for SPY (trailed the market by 85.3%). The current 89.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.